Research Site

Deszk 6772

1 studies enrolling now · 8 studies all time

What they study most

Chronic Obstructive Pulmonary Disease, Non Small Cell Lung Carcinoma NSCLC, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line, Non-Small-Cell Lung Carcinoma NSCLC, Non-small Cell Lung Cancer NSCLC, Small Cell Lung Carcinoma Extensive Disease, Stage IB-IIIA Non-small Cell Lung Carcinoma

Studies at this site

• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC — Recruiting now
• Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) — Running, not enrolling
• Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) — Running, not enrolling
• Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) — Running, not enrolling
• Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) — Running, not enrolling
• AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. — Running, not enrolling
• This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer. — Completed
• A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD — Completed